Annovis Bio (ANVS) vs eXoZymes (EXOZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Annovis Bio (ANVS) has outperformed eXoZymes (EXOZ) over the past year, losing 48.5% versus a loss of 59.7%. Annovis Bio is the larger company by market cap ($49.9 million vs $49.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANVS | EXOZ |
|---|---|---|
| Share price | $1.17 | $5.27 |
| Market cap | $49.93M | $49.04M |
| 1-day change | -3.31% | -4.87% |
| YTD return | -66.18% | -51.65% |
| 1-year return | -48.46% | -59.68% |
| 5-year return | -95.82% | — |
| EPS (TTM) | $-1.75 | $-1.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.50 | $18.40 |
| 52-week low | $1.04 | $4.35 |
| Distance from 52-week high | -78.73% | -71.36% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +797.44% | — |
| Average volume | 884.63K | 6.97K |
| Shares outstanding | 42.68M | 9.30M |
| Employees | 7 | 32 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANVS has outperformed EXOZ by 11.2 percentage points over the past year.
About Annovis Bio
ANVS stock →Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease.
Healthcare · Biotechnology · 7 employees
About eXoZymes
EXOZ stock →eXoZymes, Inc. operates as a development stage biotechnology company.
Healthcare · Biotechnology · 32 employees
ANVS vs EXOZ FAQ
Which is bigger, Annovis Bio or eXoZymes?
Annovis Bio (ANVS) is larger, with a market capitalization of $49.93M compared with $49.04M for eXoZymes (EXOZ).
Which stock has performed better over the past year, ANVS or EXOZ?
ANVS returned -48.46% over the past 12 months, compared with -59.68% for EXOZ (price return, excluding dividends). Past performance does not predict future results.
Are Annovis Bio and eXoZymes in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.